In an interview conducted at the European Hematology Association Congress 2022 in Vienna, Austria, Fadi Haddad, MD, from MD Anderson Cancer Center, Houston, TX, discussed results from a study designed to investigate the factors associated with successful treatment-free remission in patients with chronic myeloid leukemia following discontinuation of treatment with dasatinib, imatinib, and nilotinib. A deep molecular response rate of 4 (MR4) or MR4.5 for 5 years or longer was found to be the most important indicator for successful treatment-free remission. Notably, patients who relapsed following treatment discontinuation were found to be able to regain a deep molecular response.